Good evening :)
$
₹
Haleon plc

Haleon plc

HLN

NYSE
Asset Logo

Haleon plc

HLN

NYSE
$9.290.70% (+0.06)
$
₹
$9.290.70% (+0.06)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Large Cap

With a market cap of $38.9B the stock is ranked 398

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

18.04
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.75
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.49
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.99
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

14.55%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

2.24%

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
3 analysts
Hold
2 analysts
Sell
0 analyst

Price Upside

+17.62%

Earnings Growth

—

Rev. Growth

+2.36%

See Detailed Forecast

Company Profile

Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc has a collaboration agreement with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global win as one strategy. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
32.47%
32.47%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
56.57%
56.57%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
36.15%
36.15%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.2%
30.2%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
48.38%
48.38%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 17.62% growth, versus a trailing 3-year CAGR of 4.15%.

2026
Current$8.84Baseline
Analyst Target - 1 year
Target$10.4+17.62%

All values in $

202220232024202520262027$8.00$9.15$10.29Target+17.62%
2026
Current$8.84Baseline
Analyst Target - 1 year
Target$10.4+17.62%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 2.36% growth, versus a trailing 3-year CAGR of 0.53%.

2025
Current$11.03Baseline
Forecast for Dec 2026
High$11.31+2.62%
Average$11.29+2.36%
Low$11.24+1.94%

All values in $ Billion

2021202220232024202520269.5410.8511.3011.2311.03Low+1.94%Average+2.36%High+2.62%
2025
Current$11.03Baseline
Forecast for Dec 2026
High$11.31+2.62%
Average$11.29+2.36%
Low$11.24+1.94%

All values in $ Billion

Financials

Financials

Income

Balance Sheet

Cash Flow

2.7
0.4
5.4
0.8
5.5
0.8
5.6
0.7
Q1 2025
Q2 2025
Q4 2025
Q2 2026
Revenue
Net Income
Financial YearQ3 2023Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q4 2025Q2 2026
Total Revenue2.795.562.915.692.785.532.745.485.515.64
Net Income0.360.360.420.720.480.710.400.800.850.76
Net Profit Margin13.04%6.50%14.49%12.75%17.44%12.92%14.70%14.70%15.51%13.60%
See CostsAll values in $ Billion

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Haleon plc 18.041.751.99
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare HLN with any stock or ETF
Compare HLN with any stock or ETF
Comparing from
HLN
ABBV
AMGN
Loading...

Frequently asked questions

  1. Haleon plc (HLN) share price today is $9.29 as of November 5, 2026 at 8:25 PM IST. The stock touched a day high of $9.29 and a day low of $9.23.

  2. Haleon plc stock trades on NYSE under the ticker symbol HLN.

  3. Haleon plc's market capitalization is $38.85B as of November 5, 2026 at 8:25 PM IST.

  4. Haleon plc's price-to-earnings (P/E) ratio is 18.04 as of November 5, 2026.

  5. Haleon plc's price-to-book (P/B) ratio is 1.75 as of November 5, 2026.

  6. Yes, Haleon plc pays a dividend, with a current dividend yield of 2.24%.

  7. Yes, You can buy Haleon plc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Haleon plc shares in three steps: 1. Search Haleon plc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Haleon plc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Haleon plc (HLN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.0758 shares at the current price of $9.29.

Loading...